Cardiology

  • Eruptive xanthoma: Warning sign of systemic disease
    Gillian Roga, MD and Madhukhara Jithendriya, DNB
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 715-716; DOI: https://doi.org/10.3949/ccjm.83a.15126

    Initial laboratory testing showed a triglyceride level of 5,742 mg/dL.

  • Update in perioperative cardiac medicine
    Steven L. Cohn, MD, MS, FACP, SFHM, Suparna Dutta, MD, MPH, Barbara A. Slawski, MD, MS, FACP, SFHM, Paul J. Grant, MD, SFHM, FACP and Gerald W. Smetana, MD, FACP
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 723-730; DOI: https://doi.org/10.3949/ccjm.83a.16076

    Risk assessment, risk reduction, antiplatelet therapy after stent placement, and bridging anticoagulation.

  • The ABCs of managing systolic heart failure: Past, present, and future
    Ike S. Okwuosa, MD, Oluseyi Princewill, MD, MPH, Chiemeke Nwabueze, MD, Lena Mathews, MD, Steven Hsu, MD, Nisha A. Gilotra, MD, Sabra Lewsey, MD, MPH, Roger S. Blumenthal, MD and Stuart D. Russell, MD
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 753-765; DOI: https://doi.org/10.3949/ccjm.83a.16006

    Digitalis, diuretics, and bedrest have given way to neurohormonal blockade and physical rehabilitation.

  • Evolution of heart failure management: Miles to go
    James B. Young, MD
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 766-768; DOI: https://doi.org/10.3949/ccjm.83a.16043

    Despite progress, too many patients still suffer, too many die too young, and the costs are still too great.

  • Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Meghana Halkar, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine September 2016, 83 (9) 675-688; DOI: https://doi.org/10.3949/ccjm.83a.15092

    After drug-eluting stent placement, at least 12 months of dual antiplatelet therapy is recommended. Would longer be better?

  • Should patients with stable ischemic heart disease undergo revascularization?
    Michael Chenier, MD, MPH and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine August 2016, 83 (8) 567-570; DOI: https://doi.org/10.3949/ccjm.83a.15093

    The benefi t is much less clear for stable disease than for acute coronary syndromes.

  • Blood pressure targets (March 2016)
    Jonathan Lee Edwards, MD
    Cleveland Clinic Journal of Medicine July 2016, 83 (7) 487-488; DOI: https://doi.org/10.3949/ccjm.83c.07002
  • Blood pressure targets (March 2016)
    Özgür Yilmaz, MD
    Cleveland Clinic Journal of Medicine July 2016, 83 (7) 487; DOI: https://doi.org/10.3949/ccjm.83c.07001

    Readers comment on the Systolic Blood Pressure Intervention Trial (March 2016).

  • In reply: Blood pressure targets (March 2016)
    George Thomas, MD, FACP, FASN, Joseph V. Nally, MD and Marc A. Pohl, MD
    Cleveland Clinic Journal of Medicine July 2016, 83 (7) 488-489; DOI: https://doi.org/10.3949/ccjm.83c.07003
  • Premature ventricular contractions: Reassure or refer?
    Baris Akdemir, MD, Hirad Yarmohammadi, MD, MPH, M. Chadi Alraies, MD, FACP and Wayne O. Adkisson, MD, FHRS, FACC
    Cleveland Clinic Journal of Medicine July 2016, 83 (7) 524-530; DOI: https://doi.org/10.3949/ccjm.83a.15090

    Many patients need only reassurance and do not need to see a cardiologist.

Pages